TY - JOUR

T1 - Oxygenated Perfluorochemicals Improve Cell Survival during Reoxygenation by Pacifying Mitochondrial Activity

AU - Arab, Amina

AU - Kümmerer, Klaus

AU - Wang, Jin

AU - Bode, Christoph

AU - Hehrlein, Christoph

PY - 2008/5

Y1 - 2008/5

N2 - Perfluorochemicals (PFCs) are known to provide a unique tool for controlled uptake and delivery of oxygen. We have characterized the effects of incremental oxygen delivery on cell viability of human ischemic cardiomyocytes using chemically inert PFCs as oxygen carrier. We have found that cell viability after prolonged ischemia depends on the dose of oxygen supplementation by oxygenated (ox) PFCs during reoxygenation. Although reoxygenation with the transient addition of oxPFCs in high concentrations (2250 μM O2 in 0.4 μM PFCs) results in decreased cell viability compared with normoxic reoxygenation, cell survival increases by 30 ± 4% after reoxygenation with moderate oxPFC concentrations (750 μM O2 in 0.1 μM PFCs). Immunoblot analysis revealed that oxPFC-supplemented reoxygenation causes marked (16-fold) deactivation of death-associated protein kinase (DAPK) signaling an increase in mitochondrial membrane potential and a decreased steady-state level of superoxide by 19 ± 3%. Reoxygenation with oxPFCs is further responsible for a 2-fold activation of AMP-activated protein kinase (AMPK) signaling an inadequate ATP supply by oxidative phosphorylation during reoxygenation. Addition of oxPFCs stabilizes both hypoxia-inducible factor (HIF) 1-α and 2-α during reoxygenation. Overall, these results indicate that moderate doses of oxPFCs can improve cell survival during reoxygenation, causing deactivation of DAPK, up-regulation of AMPK, and HIF1-α and 2-α stabilization. These effects of oxPFCs are dose-dependent, and they lead to a stabilization of the mitochondrial membrane potential, decreased steady-state levels of superoxide, and pacification of mitochondrial activity. Copyright © 2008 by The American Society for Pharmacology and Experimental Therapeutics.

AB - Perfluorochemicals (PFCs) are known to provide a unique tool for controlled uptake and delivery of oxygen. We have characterized the effects of incremental oxygen delivery on cell viability of human ischemic cardiomyocytes using chemically inert PFCs as oxygen carrier. We have found that cell viability after prolonged ischemia depends on the dose of oxygen supplementation by oxygenated (ox) PFCs during reoxygenation. Although reoxygenation with the transient addition of oxPFCs in high concentrations (2250 μM O2 in 0.4 μM PFCs) results in decreased cell viability compared with normoxic reoxygenation, cell survival increases by 30 ± 4% after reoxygenation with moderate oxPFC concentrations (750 μM O2 in 0.1 μM PFCs). Immunoblot analysis revealed that oxPFC-supplemented reoxygenation causes marked (16-fold) deactivation of death-associated protein kinase (DAPK) signaling an increase in mitochondrial membrane potential and a decreased steady-state level of superoxide by 19 ± 3%. Reoxygenation with oxPFCs is further responsible for a 2-fold activation of AMP-activated protein kinase (AMPK) signaling an inadequate ATP supply by oxidative phosphorylation during reoxygenation. Addition of oxPFCs stabilizes both hypoxia-inducible factor (HIF) 1-α and 2-α during reoxygenation. Overall, these results indicate that moderate doses of oxPFCs can improve cell survival during reoxygenation, causing deactivation of DAPK, up-regulation of AMPK, and HIF1-α and 2-α stabilization. These effects of oxPFCs are dose-dependent, and they lead to a stabilization of the mitochondrial membrane potential, decreased steady-state levels of superoxide, and pacification of mitochondrial activity. Copyright © 2008 by The American Society for Pharmacology and Experimental Therapeutics.

KW - AMP- activated protein kinase

KW - cell viability

KW - death-associated protein kinase

KW - hypoxia-inducible factor

KW - mitochondria

KW - perfluorochemical

KW - Chemistry

UR - http://www.scopus.com/inward/record.url?scp=42449097233&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/f3209de9-4278-36d8-a7f3-23726ea678ed/

U2 - 10.1124/jpet.107.133710

DO - 10.1124/jpet.107.133710

M3 - Journal articles

C2 - 18305017

VL - 325

SP - 417

EP - 424

JO - The Journal of Pharmacology and Experimental Therapeutics

JF - The Journal of Pharmacology and Experimental Therapeutics

SN - 1521-0103

IS - 2

ER -